Roivant Sciences (NASDAQ:ROIV – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.
Analyst Ratings
This is a breakdown of recent ratings for Roivant Sciences and HCW Biologics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Roivant Sciences | 1 | 1 | 10 | 1 | 2.85 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
Roivant Sciences currently has a consensus price target of $35.14, indicating a potential upside of 0.59%. HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 920.41%. Given HCW Biologics’ higher probable upside, analysts plainly believe HCW Biologics is more favorable than Roivant Sciences.
Volatility & Risk
Valuation and Earnings
This table compares Roivant Sciences and HCW Biologics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Roivant Sciences | $8.26 million | 3,054.56 | -$299.77 million | ($0.53) | -65.91 |
| HCW Biologics | $50,000.00 | 108.19 | -$7.96 million | ($27.60) | -0.11 |
HCW Biologics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Roivant Sciences and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Roivant Sciences | -3,534.96% | -22.94% | -21.53% |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
Insider and Institutional Ownership
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Roivant Sciences beats HCW Biologics on 9 of the 15 factors compared between the two stocks.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
